H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells
暂无分享,去创建一个
P. Vyas | G. Buck | D. Knapp | O. Heidenreich | Laura J. Godfrey | P. Menéndez | T. Milne | A. Roy | I. Roberts | H. Geng | P. Ancliff | N. Elliott | S. Inglott | Joe R. Harman | Ross Thorne | Nicholas T. Crump | S. Rice | I-Jun Lau | Thomas R. Jackson | C. Connor | Sorcha O’Byrne | N. Crump | T. Jackson | J. Harman
[1] B. Povinelli,et al. Discovery of a CD10 negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs. , 2019, Blood.
[2] R. Pieters,et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Jiajia Lin,et al. The promotion of nanoparticle delivery to two populations of gastric cancer stem cells by CD133 and CD44 antibodies. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[4] P. Vyas,et al. DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation , 2019, Nature Communications.
[5] Paul J. Hoffman,et al. Comprehensive Integration of Single-Cell Data , 2018, Cell.
[6] K. Sneppen,et al. Theoretical analysis of Polycomb-Trithorax systems predicts that poised chromatin is bistable and not bivalent , 2019, Nature Communications.
[7] E. Eyras,et al. CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity , 2019, Leukemia.
[8] I. Varela,et al. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis , 2019, Haematologica.
[9] F. Gutiérrez-Agüera,et al. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia , 2019, Leukemia.
[10] G. Liou,et al. CD133 as a regulator of cancer metastasis through the cancer stem cells. , 2019, The international journal of biochemistry & cell biology.
[11] S. Lomvardas,et al. Lhx2/Ldb1-mediated trans interactions regulate olfactory receptor choice , 2018, Nature.
[12] Christoph Hafemeister,et al. Comprehensive integration of single cell data , 2018, bioRxiv.
[13] Kashish Chetal,et al. The Human Cell Atlas bone marrow single-cell interactive web portal , 2018, Experimental hematology.
[14] Y. Zhai,et al. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells , 2018, Leukemia.
[15] Thomas Gregor,et al. Dynamic interplay between enhancer-promoter topology and gene activity , 2018, Nature Genetics.
[16] K. Ottersbach,et al. The fetal liver lymphoid-primed multipotent progenitor provides the prerequisites for the initiation of t(4;11) MLL-AF4 infant leukemia , 2018, Haematologica.
[17] J. Telenius,et al. A tissue-specific self-interacting chromatin domain forms independently of enhancer-promoter interactions , 2017, Nature Communications.
[18] E. Clappier,et al. The MLL recombinome of acute leukemias in 2017 , 2017, Leukemia.
[19] Thomas A Milne,et al. Mouse models of MLL leukemia: recapitulating the human disease. , 2017, Blood.
[20] M. Konopleva,et al. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia , 2017, Cell reports.
[21] Salam A. Assi,et al. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. , 2016, Cancer cell.
[22] P. Houghton,et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. , 2016, Blood.
[23] D. Ellison,et al. Multi-organ Mapping of Cancer Risk , 2016, Cell.
[24] Howard Y. Chang,et al. Lineage-specific and single cell chromatin accessibility charts human hematopoiesis and leukemia evolution , 2016, Nature Genetics.
[25] P. Vyas,et al. Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage , 2016, The Journal of experimental medicine.
[26] Wendy A. Bickmore,et al. Shh and ZRS enhancer colocalisation is specific to the zone of polarising activity , 2016, Development.
[27] R. Stam,et al. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. , 2015, Blood.
[28] K. Coombes,et al. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199 , 2015, Cell reports.
[29] J. Telenius,et al. Multiplexed analysis of chromosome conformation at vastly improved sensitivity , 2015, Nature Methods.
[30] Cheng Cheng,et al. The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias , 2015, Nature Genetics.
[31] David A. Orlando,et al. Quantitative ChIP-Seq normalization reveals global modulation of the epigenome. , 2014, Cell reports.
[32] K. Helin,et al. Gene silencing triggers polycomb repressive complex 2 recruitment to CpG islands genome wide. , 2014, Molecular cell.
[33] Howard Y. Chang,et al. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position , 2013, Nature Methods.
[34] N. Brockdorff,et al. Chromatin Sampling—An Emerging Perspective on Targeting Polycomb Repressor Proteins , 2013, PLoS genetics.
[35] W. Choi,et al. The MLL recombinome of acute leukemias in 2013 , 2013, Leukemia.
[36] Thomas A. Milne,et al. RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction , 2013, Cell reports.
[37] Sarah Filippi,et al. Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21 , 2012, Proceedings of the National Academy of Sciences.
[38] T. Milne,et al. Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis , 2012, Cancers.
[39] Anthony B Mak,et al. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription. , 2012, Cancer research.
[40] Lars Bullinger,et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.
[41] C. Pui,et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Kevin K Dobbin,et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. , 2010, Blood.
[43] T. Dingermann,et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. , 2010, Blood.
[44] Davis J. McCarthy,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[45] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[46] P. Kearns,et al. Expression of CD133 on leukemia-initiating cells in childhood ALL. , 2009, Blood.
[47] Richard A Young,et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. , 2008, Genes & development.
[48] A. Chinnaiyan,et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. , 2007, Blood.
[49] M. Loh,et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). , 2007, Blood.
[50] M. D. Boer,et al. The MLL recombinome of acute leukemias , 2006, Leukemia.
[51] J. Hess,et al. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. , 2005, Cancer research.
[52] Renato Paro,et al. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. , 2004, Annual review of genetics.
[53] F. Prósper,et al. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen , 2002, Transfusion.
[54] C. Bartram,et al. The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin‐7 , 1994, British journal of haematology.
[55] A. Sandberg,et al. Cytogenetic characterization of putative human myeloblastic leukemia cell lines (ML-1, -2, and -3): origin of the cells. , 1986, Cancer research.
[56] A. Morley,et al. RCH-ACV: a lymphoblastic leukemia cell line with chromosome translocation 1;19 and trisomy 8. , 1986, Cancer Genetics and Cytogenetics.
[57] S. Kaur,et al. What is B-Cell Acute Lymphoblastic Leukemia ? , 2020 .
[58] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[59] Tabiwang N. Arrey,et al. The leukemogenic AF4–MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures , 2011, Leukemia.
[60] Jinlan Pan,et al. Acute Myeloid Leukemia , 2021, Cancers in the Urban Environment.
[61] A. Órfão,et al. Immunophenotypic characteristics of PB-mobilised CD34+ hematopoietic progenitor cells. , 2001, Journal of biological regulators and homeostatic agents.
[62] T. Haferlach,et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. , 2001, Haematologica.